MAM
KALV

Meeder Asset Management’s KalVista Pharmaceuticals KALV Stock Holding History

Meeder Asset Management’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-137
Closed -$2K – 2422
2019
Q4 		$2K Buy
+137
New +$1.79K ﹤0.01% 2020

Other funds holding KALV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Meeder Asset Management's KALV Position: Q1 2020 in Review

Meeder Asset Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2020, closing a stake of 137 shares — an estimated $2K sold.

Meeder Asset Management first reported a position in KALV in Q4 2019 and held it in 1 quarter. The position peaked at $2K in Q4 2019. 69 funds tracked by Wall St. Rank hold KALV as of Q1 2020.

  • Meeder Asset Management reported no remaining KalVista Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Meeder Asset Management sold 137 KalVista Pharmaceuticals shares in Q1 2020, an estimated $2K.
  • Meeder Asset Management first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Meeder Asset Management's KalVista Pharmaceuticals position peaked at $2K in Q4 2019.
  • 69 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2020.

Based on Meeder Asset Management's 13F filing for Q1 2020, filed 15 May 2020.